EligibleTrials

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

Recruiting · NCT05104983 · Interventional (participants receive a specific treatment) · Lead sponsor: Darcy Krueger

View the official record on ClinicalTrials.gov →
Multiple sclerosisEpilepsy

Interventions studied

PlaceboSirolimus

What this trial is about

This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants. This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).

Who can take part

Age range
1 Day to 6 Months
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

22 locations listed across 10 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.